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tion were evaluated in 10 patients with chronic (New York Heart Association class III and IV) nonischemic congestive heart failure. Central hemodynamic responses demonstrated a modest decrease in mean arterial pressure, pulmonary capillary wedge pressure and systemic vascular resistance (12%, 15% and 29%, respectively), while the cardiac index increased from 2.3 ± 0.1 to 3.1 ± 0.3 and left ventricular stroke work index from 24 ± 3.7 to 28 ± 3.4 (p < 0.01). Heart rate and diastolic filling time did not change. Coronary blood flow increased approximately 50%, from 144 i 17 to 218 ± 30 ml/min, and coronary vascular resistance decreased from 0.55 ± 0.09 to 0.36 ± 0.08 mm Hg/ml/min (both p < 0.01). Oral hydralazine increased myocardial oxygen consumption by 33%, from 15 ± 1.6 to 20 ± 2.7 ml/min. Despite this moderate augmentation in myocardial oxygen consumption, the arterial-coronary sinus oxygen difference decreased from 104 ± 6.2 to 94 ± 7.5 and the myocardial oxygen extraction ratio decreased from 71% to 64% (bothp < 0.05). The ratio of coronary vascular resistance to systemic vascular resistance decreased with hydralazine therapy, while coronary blood flow increased from 3.5% to 4.3% of total cardiac output. In this group of patients with nonischemic cardiomyopathy, hydralazine had a favorable effect on the coronary circulation and improved the critical myocardial oxygen supply-demand ratio.
HYDRALAZINE induces peripheral circulatory vasodilation through direct relaxation of the arteriolar smooth muscle.1 2 Early studies2 3 suggested nonuniformity of vasodilation in systemic circulation. In the setting of congestive heart failure, recent reports have demonstrated augmentation of renal and forearm blood flow with little effect on the hepatic circulation.4'6 This study was designed to assess the effects of oral hydralazine on the coronary vascular system in patients with chronic severe nonischemic congestive heart failure. From Patients and Methods Ten patients with congestive heart failure (New York Heart Association functional class III and IV) were studied. The group consisted of five females and five males, mean age 48 years (range 23-58 years). Each patient had nonischemic cardiomyopathy documented by cardiac catheterization performed within 6 weeks of the study. The left ventricular ejection fraction of all patients was less than 35% and eight patients had resting left ventricular end-diastolic filling pressure greater than 20 mm Hg. The patients had been maintained on conventional cardiac medications -10 were taking digitalis, nine diuretics, four nitrates, and four antiarrhythmics. Diuretics and nitrates were discontinued 48 hours before the beginning of the study. Exclusion criteria included anemia, primary hepatic dysfunction, uremia, primary valvular heart disease or evidence of active myocarditis.
Protocol
Each patient gave written informed consent before study. Before the control period, a balloon-tipped, triple-lumen thermodilution catheter was placed in the pulmonary artery to measure central hemodynamic variables. A thin-walled arterial catheter, placed in the radial artery, continuously monitored systemic blood pressure and provided a port for arterial blood samples. Coronary sinus cannulation was performed under fluoroscopic control with a dual thermistor coronary sinus catheter. Catheter position and stability were confirmed by contrast angiography and temperature assessment according to the techniques described by Ganz et al. 7 With the patient in the supine resting state, central hemodynamic measurements included systemic arterial, pulmonary arterial and pulmonary capillary wedge pressure using Electronics for Medicine M2101 pressure amplification units. Cardiac output (thermodilution technique8) was measured in triplicate with less than 10% variation using an Instrumentation Laboratory 601 computer and 602 recorder. Coronary blood flow measurements (thermodilution technique7) were performed with a #7F model CCS-7U-90B dual thermistor coronary sinus catheter interphased with a Wilton Webster CBA-210 two-channel Wheatstone bridge with selfcontained solid-state preamplifiers.7 " A multichannel Electronics for Medicine recorder transcribed simultaneous thermistor signals. Oxygen content was determined by the electrochemical method (Lex-O2-Con, Lexington Instruments). Both hemodynamic and coronary flow measurements were made hourly during a 4-hour control period to ensure stability of baseline data. Patients with a coefficient of variation of more than 10% (central or coronary hemodynamics) during the control period were excluded from the study. After the control period, each patient received 1 mg/kg of oral hydralazine. Measurements were repeated every 60 minutes over the next 4 hours.
The following central hemodynamic calculations were made: cardiac index; stroke volume index; mean arterial pressure (diastolic pressure + [systolicdiastolic pressure]/3); systemic vascular resistance (mean systemic arterial pressure X 80/cardiac output); and left ventricular stroke work index (stroke volume index X mean arterial pressurepulmonary wedge pressure difference X 0.0136). Coronary hemodynamic calculations included coronary sinus flow, calculated as F1 X 1.17 X ([TB - TI]/[TB-TM] -1), where F1 = rate of injectate (ml/ min), 1.17 is a constant accounting for specific heat and density of both blood and indicator, and TB, T1, and TM = the temperature of blood, indicator, and blood indicator mixture, respectively; and coronary vascular resistance = (mean arterial pressurepulmonary wedge pressure)/coronary sinus flow. Metabolic calculations included oxygen consumption index (cardiac output X arterial-pulmonary artery oxygen difference/body surface area); myocardial extraction ratio (arterial-coronary sinus oxygen difference/arterial oxygen X 100); and myocardial oxygen consumption (coronary sinus flow X arterial-coronary sinus oxygen difference).
Time and pressure calculations, estimates of myocardial oxygen consumption and coronary blood flow, included systolic pressure time index (systemic systolic pressure X left ventricular ejection time X heart rate; diastolic filling time ([cardiac cycleelectromechanical systole] X heart rate); diastolic pressure time index ([systemic diastolic pressurepulmonary capillary wedge pressure] X diastolic filling period X heart rate).10 Left ventricular ejection time and diastolic filling were calculated by measuring systolic and diastolic time intervals1" with an Electronics for Medicine Echo IV unit. Recordings were made at a paper speed of 100 mm/sec. Abbreviations: CSF = coronary sinus blood flow; CSF/CO X 100 = percent coronary circulation; SA -PCW = mean systemic blood pressurepulmonary wedge pressure difference; CVR = coronary vascular resistance; CS 02 = coronary sinus oxygen content; (A-CS) 02 = arterial-coronary sinus oxygen difference; 02 (% extraction) = myocardial extraction ratio; MV02 = myocardial oxygen consumption; C = control; H = hydralazine.
Statistical Analysis
The mean ± SEM was determined before and after hydralazine. Control values represent the average of four determinations during the 4-hour pretreatment period. Posthydralazine values represent the average of the 2-and 3-hour responses. Data were compared using the t test for paired and unpaired analysis when appropriate. A p < 0.05 was considered significant.
Results
The central hemodynamic data obtained during the control and posthydralazine periods are presented in table 1. The moderately severe degree of cardiac dysfunction is confirmed by the depressed control mean cardiac index and elevated mean pulmonary capillary wedge pressure. The elevated control systemic vascular resistance significantly diminished with oral hydralazine, with a concomitant increase in cardiac index and stroke volume index. The pulmonary capillary wedge and systemic arterial pressure decreased modestly. Heart rate was not significantly altered. Left ventricular stroke work index increased significantly with hydralazine therapy despite a 10% -60
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-40--20 -40 -60 -80 -100 A SVR % decrease in the mean systemic arterial pressure-pulmonary capillary wedge pressure difference. The total body oxygen consumption index did not change significantly with hydralazine. Coronary hemodynamic and myocardial energetic data, determined at baseline and after hydralazine, are presented in table 2 and figures 1-4. Oral hydralazine markedly diminished coronary vascular resistance with concomitant augmentation of coronary sinus blood flow. This arterial vasodilator elicited a greater decrease in coronary vascular resistance than total systemic vascular resistance (35% vs 29%) and the ratio of percent change was 1.7 (figs. IA and 2A). The percentage of total cardiac output directed to the coronary circulation increased from 3.5% to 4.3% and the ratio of percent change of coronary flow to cardiac output was 1.9 (figs. 1 and 2). Despite an increase in myocardial oxygen consumption with hydralazine therapy, the coronary sinus oxygen content increased, the arterial-coronary sinus oxygen difference was diminished and the myocardial oxygen extraction ratio decreased (all p < 0.05) ( fig. 3 ). The 32% increase in myocardial oxygen consumption was accom- panied by a 51 % increase in coronary blood flow. Sequential coronary changes both during control and after hydralazine are presented in 
Discussion
Attenuation of cardiac output, demonstrated in the congestive heart failure patient, is accompanied by an alteration of perfusion of regional vascular beds. '2' 13 Renal, hepatic and skeletal muscle blood flow is reduced at rest in patients with myocardial decompensation.ff 14 Coronary blood flow per unit mass of myocardium is diminished in congestive cardiomyopathy.16 Several investigators have noted the increased susceptibility of subendocardial tissue to ischemia and necrosis, most notably in patients with left ventricular hypertrophy (increased myocardial muscle mass).'0' [16] [17] [18] Increased heart rate and decreased perfusion pressure both tend to jeopardize myocardial blood flow.'9-21 Our 10 patients, who had nonischemic cardiomyopathy, demonstrated normal total coronary blood flow at rest; however, because of significant ventricular hypertrophy, the flow per unit mass was depressed (41 ± 12 ml/100 g * min). Although vasodilators induce improved central hemodynamic measurements, they also lower blood pressure and may induce or aggravate myocardial ischemia by decreasing perfu- sion pressure, increasing left ventricular work, or possibly shunting flow away from the coronary vascular bed (to the systemic circulation).22 24 The patients in this study responded to oral hydralazine with a marked decrease in coronary vascular resistance. Coronary vascular dilation was more pronounced than that demonstrated in the remainder of the systemic circulation and the percent augmentation of coronary flow (5 1 %) significantly exceeded that noted in total cardiac index (34%) ( fig. 4 ). Coronary sinus flow represented 3.5% of cardiac output at baseline. After hydralazine therapy, 4.3% of cardiac output was directed to the coronary vascular bed. With vasodilator therapy, coronary vascular resistance decreased 35% and systemic vascular resistance decreased 29% ( fig. 4 ), accounting for a redistribution of flow to the coronary circulation after pharmacologic manipulation.
Myocardial oxygen consumption increased 33% with hydralazine therapy. The increase in oxygen demand was accompanied by a 34% increase in cardiac index and a modest 17% elevation of left ventricular stroke work index. This increase in myocardial oxygen consumption, which could induce subendocardial ischemia, was mitigated by an overall increase in coronary blood flow and oxygen delivery. Enhancement of myocardial energetics was reflected by an increase in coronary sinus oxygen content, a significant decrease coronary vascular resistance; MVO2 = myocardial oxygen in the arterial-coronary sinus oxygen difference, and diminished oxygen extraction ratio. Although no clinical or electrocardiographic evidence of ischemia was noted, these findings do not exclude the possibility of coronary vascular arterial-venous shunting or preferential underperfusion of subendocardium. However, requirements for nutritional flow appeared to be completely compensated for by the increased coronary sinus flow and, in fact, the elevation of coronary sinus oxygen content suggests an improved supplydemand balance.
The major factors that affect myocardial oxygen demand are heart rate, wall stress and contractility.'9 21 Systemic blood pressure dropped with hydralazine therapy and, although not directly measured in this study, earlier investigators have demonstrated vasodilator-induced decreases in left ventricular chamber radius associated with diminished ventricular filling pressures.25 These changes are consistent with an overall decrease in myocardial wall stress. The systolic pressure-time index did not change. This suggests that increased contractility may account for the change in myocardial oxygen demand. Early studies suggested that hydralazine had no direct effect on the myocardium; however, more recent reports demonstrate direct inotropic effects.2 2629 Increases in cardiac output, stroke volume, left ventricular stroke work, and myocardial oxygen consumption without significant elevation of heart rate and wall stress are consistent with hydralazine enhancement of myocardial contractility. Coronary blood flow is dependent on the perfusion pressure, vascular resistance and diastolic time."' 19, 20 The actual driving pressure across the coronary vascular bed is an issue of continuing controversy,20 and in this study was estimated from both the mean aortic-pulmonary capillary wedge pressure difference (table 2) and the systemic diastolic arterial pressure-pulmonary capillary wedge difference (table 4) . Among our patients, the coronary pressure gradient dropped approximately 1%, with no statistically significant change in diastolic time or the diastolic pressure-time index (table 4) . Coronary vascular resistance, however, decreased dramatically with hydralazine therapy. Numerous studies support the concept that myocardial oxygen demand plays the predominant role in controlling coronary vascular resistance. '9-21, 30 Intrinsic local metabolic factors usually supersede both neurohumoral and myogenic influence.'9' 30 Several investigators have noted a close parallel relationship between myocardial oxygen consumption and coronary blood flow.'9' 81 In our study, hydralazine induced a greater increase in coronary blood flow than myocardial oxygen demand (51% vs 33%). This more profound effect on coronary flow is probably indicative of a direct effect of hydralazine on coronary arteriolar smooth muscle. In the face of an increase in the coronary venous oxygen content with hydralazine, the reduction in coronary resistance is probably not related to local ischemia or metabolic factors that occur with hydralazine therapy. The nature of the hydralazine effect on the coronary microcirculation remains uncertain; however, an analysis of coronary sinus effluent would suggest improvement in the critical supply-demand ratio in patients with nonischemic cardiomyopathy.
